What do systematic reviews say?

Coasting vs early unilateral follicular aspiration

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs early unilateral follicular aspiration

It is very uncertain whether coasting changes OHSS compared with early unilateral follicular aspiration (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 0.98 [0.34, 2.85]
  2 studies · 83 participants
  Very low

Coasting vs early unilateral follicular aspiration

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs early unilateral follicular aspiration

It is very uncertain whether coasting changes clinical Pregnancy compared with early unilateral follicular aspiration (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 0.67 [0.25, 1.79]
  2 studies · 83 participants
  Very low

Coasting vs early unilateral follicular aspiration

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bisphosphonates vs placebo/observation

Bisphosphonates probably leads to lower bone metastases compared with placebo/observation (moderate certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.75, 0.99]
  11 studies · 15005 participants
  Moderate

Bisphosphonates vs placebo/observation

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 7 participants
  Moderate

Bisphosphonates vs placebo/observation

Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.91 [0.83, 0.99]
  9 studies · 13949 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates leads to lower overall survival postmenopausal women compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.77 [0.66, 0.9]
  4 studies · 6048 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates showed no clear difference in overall survival: pre‐ or perimenopausal women compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 1.03 [0.86, 1.22]
  2 studies · 3501 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates showed no clear difference in disease‐free progression compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.94 [0.87, 1.02]
  7 studies · 12578 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates leads to lower disease‐free progression: postmenopausal women compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 0.82 [0.74, 0.91]
  7 studies · 8314 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates showed no clear difference in disease‐free progression: pre‐ or perimenopausal women compared with placebo/observation (high certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  HR 1.01 [0.9, 1.13]
  4 studies · 5493 participants
  High

Bisphosphonates vs placebo/observation

Bisphosphonates showed no clear difference in fracture incidence compared with placebo/observation (moderate certainty).

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.54, 1.08]
  6 studies · 7602 participants
  Moderate

Bisphosphonates vs placebo/observation

• Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 13242 participants
  High

Chemotherapy alone vs same chemotherapy plus radiotherapy

Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 0.43 [0.23, 0.82]
  3 studies · 1011 participants
  Low

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 1.1 [0.74, 1.62]
  3 studies · 2403 participants
  Moderate

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.73, 1.34]
  3 studies · 2403 participants
  High

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 1.15 [0.91, 1.45]
  3 studies · 2403 participants
  High

Chemotherapy alone vs same chemotherapy plus radiotherapy

Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.71 [0.46, 1.11]
  3 studies · 1011 participants
  Moderate